Ensitrelvir, an oral antiviral agent that targets a SARS-CoV-2 main protease (3CLpro or
Nsp5), is clinically useful against SARS-CoV-2 including its omicron variants. Since most …

Over four years have passed since the beginning of the COVID-19 pandemic. The scientific
response has been rapid and effective, with many therapeutic monoclonal antibodies and …

Resistance of SARS-CoV-2 to antivirals was shown to develop in immunocompromised
individuals receiving remdesivir. We describe an immunocompromised patient who was …

Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main
protease (Mpro) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in …

Computer-Aided Drug Design (CADD) approaches, such as those employing quantitative
structure-activity relationship (QSAR) methods, are known for their ability to uncover novel …

Drug resistance poses a significant challenge in the development of effective therapies
against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and …

The recurrent nature of coronavirus outbreaks, severity of the COVID-19 pandemic, rapid
emergence of novel variants, and concerns over the effectiveness of existing vaccines …

Inhibitors of the SARS-CoV-2 main protease (Mpro) such as nirmatrelvir (NTV) and
ensitrelvir (ETV) have proven effective in reducing the severity of COVID-19, but the …

Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for
prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in …

Here, the antiviral activity of aminoadamantane derivatives were evaluated against SARS-
CoV-2. The compounds exhibited low cytotoxicity to Vero, HEK293 and CALU-3 cells up to a …